OTSKF
Otsuka Holdings Co., Ltd.
Set alert
73.16 USD 0.00 0.00%
72.00 Day range 72.00
54.26 52-week range 79.00
- YTD
- +34.82%
- 1 year
- +27.54%
- Open
- 72.00
- Prev close
- 73.16
- Mkt cap
- 38.33B
- Vol
- 41
- Avg vol
- 13
- EPS
- 4.94
- P/E
- 14.81
More statistics
- Low
- 72.00
- High
- 72.00
- Earnings
- Nov 4, 2026
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 1.13.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 1.13 | — | — | — |
| Jul 31, 2026 | Jun 30, 2026 | 1.01 | 1.37 | +0.36 | +35.64% |
| Apr 28, 2026 | Mar 31, 2026 | 0.858 | 1.17 | +0.31 | +36.36% |
| Feb 12, 2026 | Dec 31, 2025 | 0.4771 | 0.793 | +0.32 | +66.21% |
| Oct 31, 2025 | Sep 30, 2025 | 1.05 | 1.59 | +0.54 | +51.43% |
| Jul 31, 2025 | Jun 30, 2025 | 1.04 | 1.16 | +0.12 | +11.54% |
News
- Aristotle International Equity ADR WM Q1 2026 Contributors And Detractors
- Otsuka Holdings Co., Ltd. (OTSKY) M&A Call Prepared Remarks Transcript
- Otsuka Holdings Co., Ltd. (OTSKY) Q4 2025 Earnings Call Prepared Remarks Transcript
- Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment
- Otsuka (OTCMKTS:OTSKF) Trading Up 3% – Should You Buy?
- Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle
- US FDA approves Otsuka's kidney disease drug
- Otsuka Corporation (OSUKF) Q1 FY2025 Earnings Call Transcript
Your note
Sign in to keep a note on OTSKF — it syncs with the Stock Master app.